

# Jan H M Schellens

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/876634/publications.pdf>

Version: 2024-02-01

181  
papers

16,042  
citations

28274

55  
h-index

17105

122  
g-index

184  
all docs

184  
docs citations

184  
times ranked

21209  
citing authors

#	ARTICLE	IF	CITATIONS
1	Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical Study. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 62-68.	4.7	32
2	Bioanalytical LC-MS/MS validation of therapeutic drug monitoring assays in oncology. <i>Biomedical Chromatography</i> , 2020, 34, e4623.	1.7	13
3	Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies. <i>Journal of Thoracic Oncology</i> , 2020, 15, 618-627.	1.1	254
4	Circulating epithelial tumor cell analysis in CSF in patients with leptomeningeal metastases. <i>Neurology</i> , 2020, 94, e521-e528.	1.1	40
5	Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: An IPD meta-analysis. <i>Pharmacological Research</i> , 2020, 152, 104594.	7.1	17
6	No relation between docetaxel administration route and high-grade diarrhea incidence. <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00633.	2.4	9
7	Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. <i>Lancet Oncology</i> , The, 2020, 21, 1234-1243.	10.7	297
8	Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer. <i>British Journal of Cancer</i> , 2020, 122, 1166-1174.	6.4	30
9	Phase I pharmacological study of continuous chronomodulated capecitabine treatment. <i>Pharmaceutical Research</i> , 2020, 37, 89.	3.5	12
10	Quantification of the pharmacokinetic-toxicodynamic relationship of oral docetaxel co-administered with ritonavir. <i>Investigational New Drugs</i> , 2020, 38, 1526-1532.	2.6	1
11	Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 917-930.	2.3	29
12	Population Pharmacokinetics of MCLA-128, a HER2/HER3 Bispecific Monoclonal Antibody, in Patients with Solid Tumors. <i>Clinical Pharmacokinetics</i> , 2020, 59, 875-884.	3.5	13
13	Pharmacokinetics of Capecitabine and Four Metabolites in a Heterogeneous Population of Cancer Patients: A Comprehensive Analysis. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019, 8, 940-950.	2.5	19
14	Comparison of toxicity and effectiveness between fixed-dose and body surface area-based dose capecitabine. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591983896.	3.2	10
15	DPYD genotype-guided dose individualisation of fluoropyrimidine therapy: who and how? – Authors' reply. <i>Lancet Oncology</i> , The, 2019, 20, e67.	10.7	2
16	Neutropenia and docetaxel exposure in metastatic castration-resistant prostate cancer patients: A meta-analysis and evaluation of a clinical cohort. <i>Cancer Medicine</i> , 2019, 8, 1406-1415.	2.8	13
17	Development and validation of LC-MS/MS methods for the quantification of the novel anticancer agent guadecitabine and its active metabolite Î²-decitabine in human plasma, whole blood and urine. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2019, 1109, 132-141.	2.3	10
18	A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2019, 120, 286-293.	6.4	39

#	ARTICLE	IF	CITATIONS
19	A cost analysis of upfront DPYD genotypeâ€‘guided dose individualisation in fluoropyrimidine-based anticancer therapy. <i>European Journal of Cancer</i> , 2019, 107, 60-67.	2.8	65
20	Impact of Older Age on the Exposure of Paclitaxel: a Population Pharmacokinetic Study. <i>Pharmaceutical Research</i> , 2019, 36, 33.	3.5	6
21	Enzyme linked immunosorbent assay for the quantification of nivolumab and pembrolizumab in human serum and cerebrospinal fluid. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 164, 128-134.	2.8	47
22	Development, validation, and clinical application of a high-performance liquid chromatography-tandem mass spectrometry assay for the quantification of total intracellular Î²-decibabine nucleotides and genomic DNA incorporated Î²-decibabine and 5-methyl-2-â€‘deoxycytidine. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 164, 16-26.	2.8	9
23	Effectiveness and safety of reducedâ€‘dose fluoropyrimidine therapy in patients carrying the <i>DPYD</i>*2A variant: A matched pair analysis. <i>International Journal of Cancer</i> , 2019, 144, 2347-2354.	5.1	40
24	Efficacy and safety of dabrafenib (D) and trametinib (T) in patients (pts) with <i>BRAF</i>V600Eâ€‘mutated biliary tract cancer (BTC): A cohort of the ROAR basket trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 187-187.	1.6	66
25	Solubility and bioavailability improvement of pazopanib hydrochloride. <i>International Journal of Pharmaceutics</i> , 2018, 544, 181-190.	5.2	21
26	The impact of liver resection on the dihydrouracil:uracil plasma ratio in patients with colorectal liver metastases. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 737-744.	1.9	8
27	Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2-â€‘,2-â€‘difluorodeoxyuridine and their nucleotides. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1279-1289.	2.4	26
28	Combined BRAF, EGFR, and MEK Inhibition in Patients with <i>BRAF</i>V600E-Mutant Colorectal Cancer. <i>Cancer Discovery</i> , 2018, 8, 428-443.	9.4	448
29	Bioanalytical assay for the quantification of the ALK inhibitor lorlatinib in mouse plasma using liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2018, 1083, 204-208.	2.3	16
30	PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer. <i>Clinical Pharmacokinetics</i> , 2018, 57, 427-437.	3.5	87
31	Thermal stability study of crystalline and novel spray-dried amorphous nilotinib hydrochloride. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 148, 182-188.	2.8	7
32	Capecitabineâ€‘based treatment of a patient with a novel <i>DPYD</i> genotype and complete dihydropyrimidine dehydrogenase deficiency. <i>International Journal of Cancer</i> , 2018, 142, 424-430.	5.1	15
33	A drugâ€‘drug interaction study to assess the effect of the CYP1A2 inhibitor fluvoxamine on the pharmacokinetics of dovitinib (TKI258) in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 73-80.	2.3	2
34	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 210-216.	4.7	407
35	Improved pharmacodynamic (PD) assessment of low dose PARP inhibitor PD activity for radiotherapy and chemotherapy combination trials. <i>Radiotherapy and Oncology</i> , 2018, 126, 443-449.	0.6	17
36	Clinical Pharmacokinetics of Systemically Administered Antileishmanial Drugs. <i>Clinical Pharmacokinetics</i> , 2018, 57, 151-176.	3.5	55

#	ARTICLE	IF	CITATIONS
37	Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic <i>BRAF</i> <sup>V600E</sup> Mutant Anaplastic Thyroid Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 7-13.	1.6	630
38	Diagnostic and Therapeutic Strategies for Fluoropyrimidine Treatment of Patients Carrying Multiple DPYD Variants. <i>Genes</i> , 2018, 9, 585.	2.4	10
39	Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers. <i>European Journal of Cancer</i> , 2018, 104, 210-218.	2.8	14
40	Development and validation of a quantitative method for thymidine phosphorylase activity in peripheral blood mononuclear cells. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2018, 37, 436-454.	1.1	1
41	DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. <i>Lancet Oncology</i> , 2018, 19, 1459-1467.	10.7	238
42	Quantitative bioanalytical assay for the tropomyosin receptor kinase inhibitor larotrectinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2018, 1102-1103, 167-172.	2.3	10
43	Simultaneous population pharmacokinetic modelling of plasma and intracellular PBMC miltefosine concentrations in New World cutaneous leishmaniasis and exploration of exposure-response relationships. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2104-2111.	3.0	11
44	Food-effect study on uracil and dihydrouracil plasma levels as marker for dihydropyrimidine dehydrogenase activity in human volunteers. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2761-2769.	2.4	26
45	Therapeutic drug monitoring of small molecule kinase inhibitors in oncology in a real-world cohort study: does age matter?. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2770-2778.	2.4	14
46	Review of Chromatographic Bioanalytical Assays for the Quantitative Determination of Marine-Derived Drugs for Cancer Treatment. <i>Marine Drugs</i> , 2018, 16, 246.	4.6	16
47	Macrophage Activation Marker Neopterin: A Candidate Biomarker for Treatment Response and Relapse in Visceral Leishmaniasis. <i>Frontiers in Cellular and Infection Microbiology</i> , 2018, 8, 181.	3.9	15
48	Bioanalytical liquid chromatography-tandem mass spectrometric assay for the quantification of the ALK inhibitors alectinib, brigatinib and lorlatinib in plasma and mouse tissue homogenates. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 161, 136-143.	2.8	22
49	<sup>89</sup> Zr-labeled CEA-targeted IL-2 variant immunocytokine in patients with solid tumors: CEA-mediated tumor accumulation and role of IL-2 receptor-binding. <i>Oncotarget</i> , 2018, 9, 24737-24749.	1.8	24
50	Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 157-165.	1.6	345
51	How Much Longer Will We Put Up With \$100,000 Cancer Drugs?. <i>Cell</i> , 2017, 168, 579-583.	28.9	74
52	Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity. <i>British Journal of Cancer</i> , 2017, 116, 1415-1424.	6.4	94
53	Molecular Pathways: Targeting the Protein Kinase Wee1 in Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 4540-4544.	7.0	106
54	A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic <i>BRAF</i> -Mutant Colorectal Cancer. <i>Cancer Discovery</i> , 2017, 7, 610-619.	9.4	194

#	ARTICLE	IF	CITATIONS
55	A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours. <i>European Journal of Cancer</i> , 2017, 76, 144-151.	2.8	92
56	A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination with Erlotinib in Patients with Advanced Solid Tumors. <i>Oncologist</i> , 2017, 22, 1491-1499.	3.7	23
57	A dose-escalation study of bi-daily once weekly oral docetaxel either as ModraDoc001 or ModraDoc006 combined with ritonavir. <i>European Journal of Cancer</i> , 2017, 86, 217-225.	2.8	23
58	An LC-MS/MS method for quantification of the active abiraterone metabolite 4-abiraterone (D4A) in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2017, 1068-1069, 119-124.	2.3	11
59	Clinical trial simulations in paediatric oncology: A feasibility study from the Innovative Therapies for Children with Cancer Consortium. <i>European Journal of Cancer</i> , 2017, 85, 78-85.	2.8	5
60	Dihydrofolate Reductase/Thymidylate Synthase Fine-Tunes the Folate Status and Controls Redox Homeostasis in Plants. <i>Plant Cell</i> , 2017, 29, 2831-2853.	6.6	64
61	Liquid chromatography-tandem mass spectrometric assay for the quantitative determination of the tyrosine kinase inhibitor quizartinib in mouse plasma using salting-out liquid-liquid extraction. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2017, 1061-1062, 300-305.	2.3	7
62	Improving the solubility of nilotinib through novel spray-dried solid dispersions. <i>International Journal of Pharmaceutics</i> , 2017, 529, 294-302.	5.2	28
63	<i>BRAF</i> Mutations as Predictive Biomarker for Response to Anti-EGFR Monoclonal Antibodies. <i>Oncologist</i> , 2017, 22, 864-872.	3.7	56
64	Potential Benefit of Low-Dose Candesartan in Trastuzumab-Induced Cardiotoxic Effects—Reply. <i>JAMA Oncology</i> , 2017, 3, 279.	7.1	0
65	Treatment Algorithm for Homozygous or Compound Heterozygous DPYD Variant Allele Carriers With Low-Dose Capecitabine. <i>JCO Precision Oncology</i> , 2017, 1, 1-10.	3.0	8
66	Treatment of Peritoneal Dissemination in Stomach Cancer Patients With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Rationale and Design of the PERISCOPE Study. <i>JMIR Research Protocols</i> , 2017, 6, e136.	1.0	17
67	Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer. <i>Cancers</i> , 2016, 8, 6.	3.7	28
68	Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 706-716.	2.4	44
69	Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study. <i>Cancer</i> , 2016, 122, 1434-1443.	4.1	31
70	Rs895819 in <i>MIR27A</i> improves the predictive value of <i>DPYD</i> variants to identify patients at risk of severe fluoropyrimidine-associated toxicity. <i>International Journal of Cancer</i> , 2016, 138, 2752-2761.	5.1	28
71	Reply to T. Magnes et al. <i>Journal of Clinical Oncology</i> , 2016, 34, 2434-2435.	1.6	3
72	Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With <i>TP53</i> -Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months. <i>Journal of Clinical Oncology</i> , 2016, 34, 4354-4361.	1.6	241

#	ARTICLE	IF	CITATIONS
73	Liquid chromatography-tandem mass spectrometric assay for ponatinib and N-desmethyl ponatinib in mouse plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016, 1023-1024, 24-29.	2.3	11
74	Development and validation of a rapid and sensitive UPLC-MS/MS method for determination of uracil and dihydrouracil in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 126, 75-82.	2.8	39
75	Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2016, 34, 4371-4380.	1.6	203
76	Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity - Ready for clinical practice?. <i>Cancer Treatment Reviews</i> , 2016, 50, 23-34.	7.7	76
77	Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges. <i>Oncologist</i> , 2016, 21, 1260-1268.	3.7	87
78	Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the B-Raf inhibitor encorafenib, the EGFR inhibitors afatinib, erlotinib and gefitinib and the O-desmethyl metabolites of erlotinib and gefitinib in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016, 1033-1034, 390-398.	2.3	30
79	Pharmaceutical development of an oral tablet formulation containing a spray dried amorphous solid dispersion of docetaxel or paclitaxel. <i>International Journal of Pharmaceutics</i> , 2016, 511, 765-773.	5.2	40
80	Liquid chromatography-tandem mass spectrometric assay for the T790M mutant EGFR inhibitor osimertinib (AZD9291) in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016, 1031, 80-85.	2.3	38
81	Increased risk of severe fluoropyrimidine-associated toxicity in patients carrying a G to C substitution in the first 28-bp tandem repeat of the thymidylate synthase 2R allele. <i>International Journal of Cancer</i> , 2016, 138, 245-253.	5.1	23
82	Pharmacokinetics and excretion of <sup>14</sup> C-omacetaxine in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2016, 34, 565-574.	2.6	3
83	Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 875-880.	2.3	17
84	A dose escalating phase I study of GLPG0187, a broad spectrum integrin receptor antagonist, in adult patients with progressive high-grade glioma and other advanced solid malignancies. <i>Investigational New Drugs</i> , 2016, 34, 184-192.	2.6	46
85	Angiotensin II Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer. <i>JAMA Oncology</i> , 2016, 2, 1030.	7.1	160
86	Recent developments in the chromatographic bioanalysis of approved kinase inhibitor drugs in oncology. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 130, 244-263.	2.8	26
87	Renal function, body surface area, and age are associated with risk of early-onset fluoropyrimidine-associated toxicity in patients treated with capecitabine-based anticancer regimens in daily clinical care. <i>European Journal of Cancer</i> , 2016, 54, 120-130.	2.8	40
88	Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 858-867.	7.0	28
89	Development of a Tumour Growth Inhibition Model to Elucidate the Effects of Ritonavir on Intratumoural Metabolism and Anti-tumour Effect of Docetaxel in a Mouse Model for Hereditary Breast Cancer. <i>AAPS Journal</i> , 2016, 18, 362-371.	4.4	4
90	EpCAM-based flow cytometry in cerebrospinal fluid greatly improves diagnostic accuracy of leptomeningeal metastases from epithelial tumors. <i>Neuro-Oncology</i> , 2016, 18, 855-862.	1.2	57

#	ARTICLE	IF	CITATIONS
91	Crizotinib-induced fatal fulminant liver failure. <i>Lung Cancer</i> , 2016, 93, 17-19.	2.0	22
92	Liquid chromatography-tandem mass spectrometric assay for the tyrosine kinase inhibitor afatinib in mouse plasma using salting-out liquid-liquid extraction. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016, 1012-1013, 118-123.	2.3	18
93	Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time. <i>European Journal of Cancer</i> , 2016, 54, 40-48.	2.8	110
94	Upfront Genotyping of <i>DPYD</i> to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis. <i>Journal of Clinical Oncology</i> , 2016, 34, 227-234.	1.6	279
95	Liquid chromatography-tandem mass spectrometric assay for the simultaneous determination of the irreversible BTK inhibitor ibrutinib and its dihydrodiol-metabolite in plasma and its application in mouse pharmacokinetic studies. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 118, 123-131.	2.8	39
96	Pharmacodynamics and pharmacokinetics of oral topotecan in patients with advanced solid tumours and impaired renal function. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 253-266.	2.4	10
97	Tailored Tamoxifen Treatment for Breast Cancer Patients: A Perspective. <i>Clinical Breast Cancer</i> , 2015, 15, 241-244.	2.4	18
98	Variability in bioavailability of small molecular tyrosine kinase inhibitors. <i>Cancer Treatment Reviews</i> , 2015, 41, 412-422.	7.7	103
99	Treatment Individualization in Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2015, 11, 335-344.	0.5	17
100	The use of combinations of monoclonal antibodies in clinical oncology. <i>Cancer Treatment Reviews</i> , 2015, 41, 859-867.	7.7	79
101	A Phase I Monotherapy Study of RG7212, a First-in-Class Monoclonal Antibody Targeting TWEAK Signaling in Patients with Advanced Cancers. <i>Clinical Cancer Research</i> , 2015, 21, 258-266.	7.0	32
102	Liquid chromatography-tandem mass spectrometric assay for the PI3K/mTOR inhibitor GSK2126458 in mouse plasma and tumor homogenate. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015, 107, 403-408.	2.8	4
103	Improved pharmacodynamic assay for dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells. <i>Bioanalysis</i> , 2015, 7, 519-529.	1.5	15
104	Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer. <i>British Journal of Cancer</i> , 2015, 113, 396-402.	6.4	42
105	Development of an LC-MS/MS assay for the quantitative determination of the intracellular 5-fluorouracil nucleotides responsible for the anticancer effect of 5-fluorouracil. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015, 110, 58-66.	2.8	30
106	Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses. <i>Pharmacology Research and Perspectives</i> , 2015, 3, e00131.	2.4	127
107	Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. <i>Lancet Oncology</i> , The, 2015, 16, 1639-1650.	10.7	277
108	Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis. <i>BMC Medicine</i> , 2015, 13, 156.	5.5	51

#	ARTICLE	IF	CITATIONS
109	Observations on Three Endpoint Properties and Their Relationship to Regulatory Outcomes of European Oncology Marketing Applications. <i>Oncologist</i> , 2015, 20, 683-691.	3.7	7
110	Translating <i>DPYD</i> genotype into DPD phenotype: using the <i>DPYD</i> gene activity score. <i>Pharmacogenomics</i> , 2015, 16, 1275-1284.	1.3	81
111	Systematic Review of Biomarkers To Monitor Therapeutic Response in Leishmaniasis. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1-14.	3.2	62
112	Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy. <i>Investigational New Drugs</i> , 2015, 33, 201-214.	2.6	327
113	Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFM) metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 103-103.	1.6	43
114	Semiphysiological versus Empirical Modelling of the Population Pharmacokinetics of Free and Total Cefazolin during Pregnancy. <i>BioMed Research International</i> , 2014, 2014, 1-9.	1.9	17
115	NT-23 * PHASE 1/2A STUDY OF GLUTATHIONE PEGYLATED LIPOSOMAL DOXORUBICIN (2B3-101) IN BREAST CANCER PATIENTS WITH BRAIN METASTASES (BCBM) OR RECURRENT HIGH GRADE GLIOMAS (HGG). <i>Neuro-Oncology</i> , 2014, 16, v163-v163.	1.2	10
116	Quantitative determination of azacitidine triphosphate in peripheral blood mononuclear cells using liquid chromatography coupled with high-resolution mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014, 90, 7-14.	2.8	15
117	Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours. <i>Investigational New Drugs</i> , 2014, 32, 481-488.	2.6	39
118	Practical Guidelines for Therapeutic Drug Monitoring of Anticancer Tyrosine Kinase Inhibitors: Focus on the Pharmacokinetic Targets. <i>Clinical Pharmacokinetics</i> , 2014, 53, 305-325.	3.5	190
119	Predictive Value of CYP3A and ABCB1 Phenotyping Probes for the Pharmacokinetics of Sunitinib: the ClearSun Study. <i>Clinical Pharmacokinetics</i> , 2014, 53, 261-269.	3.5	23
120	Liquid chromatography-tandem mass spectrometric assay for the light sensitive survivin suppressant sepantromium bromide (YM155) in mouse plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014, 92, 144-148.	2.8	2
121	Liquid chromatography-tandem mass spectrometric assay for the PARP inhibitor rucaparib in plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014, 88, 626-629.	2.8	14
122	Phase II and Pharmacological Study of Oral Docetaxel Plus Cyclosporin A in Anthracycline Pre-Treated Metastatic Breast Cancer. <i>Current Clinical Pharmacology</i> , 2014, 9, 139-147.	0.6	9
123	Pharmacodynamic assay of thymidylate synthase activity in peripheral blood mononuclear cells. <i>Analytical and Bioanalytical Chemistry</i> , 2013, 405, 2495-2503.	3.7	7
124	Correction of peripheral blood mononuclear cell cytosolic protein for hemoglobin contamination. <i>Analytical and Bioanalytical Chemistry</i> , 2013, 405, 2391-2395.	3.7	9
125	Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 53-62.	2.3	21
126	Taxanes: Old drugs, new oral formulations. <i>European Journal of Pharmacology</i> , 2013, 717, 40-46.	3.5	53



#	ARTICLE	IF	CITATIONS
127	Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin. <i>British Journal of Clinical Pharmacology</i> , 2013, 75, 507-521.	2.4	19
128	Oral Anticancer Drugs: Mechanisms of Low Bioavailability and Strategies for Improvement. <i>Clinical Pharmacokinetics</i> , 2013, 52, 399-414.	3.5	118
129	Concise Drug Review: Azacitidine and Decitabine. <i>Oncologist</i> , 2013, 18, 619-624.	3.7	221
130	Population pharmacokineticâ€“pharmacodynamic analysis for eribulin mesilateâ€“associated neutropenia. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, 412-424.	2.4	31
131	Lapatinib for Advanced or Metastatic Breast Cancer. <i>Oncologist</i> , 2012, 17, 536-542.	3.7	67
132	Concise Drug Review: Pazopanib and Axitinib. <i>Oncologist</i> , 2012, 17, 1081-1089.	3.7	74
133	Letter to the Editor Regarding â€œA Prospective, Controlled Study of the Botanical Compound Mixture LCS101 for Chemotherapyâ€“induced Hematological Complications in Breast Cancerâ€“by Yaalâ€“Hahoshen et al. ( <i>The Oncologist</i> 2011;16:1197â€“1202). <i>Oncologist</i> , 2012, 17, 740-741.	3.7	2
134	Mass Balance Study of [14C]Eribulin in Patients with Advanced Solid Tumors. <i>Drug Metabolism and Disposition</i> , 2012, 40, 313-321.	3.3	27
135	Evaluation of a Pharmacology-Driven Dosing Algorithm of 3-Weekly Paclitaxel Using Therapeutic Drug Monitoring. <i>Clinical Pharmacokinetics</i> , 2012, 51, 607-617.	3.5	45
136	Disposition and metabolism of 14C-dovitinib (TKI258), an inhibitor of FGFR and VEGFR, after oral administration in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 653-663.	2.3	16
137	Validation of a multiparameter flow cytometry method for the determination of phosphorylated extracellularâ€“signalâ€“regulated kinase and DNA in circulating tumor cells. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2012, 81A, 664-671.	1.5	24
138	Bioanalytical aspects of clinical mass balance studies in oncology. <i>Bioanalysis</i> , 2011, 3, 2637-2655.	1.5	6
139	Relationship between Single Nucleotide Polymorphisms and Haplotypes in <i>DPYD</i> and Toxicity and Efficacy of Capecitabine in Advanced Colorectal Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 3455-3468.	7.0	168
140	Circulating tumor cells as pharmacodynamic biomarker in early clinical oncological trials. <i>Cancer Treatment Reviews</i> , 2011, 37, 579-589.	7.7	41
141	Characterization of the in vitro activity of AZD3409, a novel prenyl transferase inhibitor. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 137-145.	2.3	5
142	Mass spectrometry in the quantitative analysis of therapeutic intracellular nucleotide analogs. <i>Mass Spectrometry Reviews</i> , 2011, 30, 321-343.	5.4	28
143	Trastuzumab. <i>Oncologist</i> , 2011, 16, 800-810.	3.7	84
144	Part 3: Pharmacogenetic Variability in Phase II Anticancer Drug Metabolism. <i>Oncologist</i> , 2011, 16, 992-1005.	3.7	25

#	ARTICLE	IF	CITATIONS
145	Part 1: Background, Methodology, and Clinical Adoption of Pharmacogenetics. <i>Oncologist</i> , 2011, 16, 811-819.	3.7	32
146	Part 4: Pharmacogenetic Variability in Anticancer Pharmacodynamic Drug Effects. <i>Oncologist</i> , 2011, 16, 1006-1020.	3.7	13
147	Part 2: Pharmacogenetic Variability in Drug Transport and Phase I Anticancer Drug Metabolism. <i>Oncologist</i> , 2011, 16, 820-834.	3.7	65
148	Standard-Dose Tegafur Combined With Uracil Is Not Safe Treatment After Severe Toxicity From 5-Fluorouracil or Capecitabine. <i>Annals of Internal Medicine</i> , 2010, 153, 767.	3.9	5
149	Bevacizumab. <i>Oncologist</i> , 2010, 15, 819-825.	3.7	194
150	Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in <i>BRCA</i> Carrier Ovarian Cancer Correlating With Platinum-Free Interval. <i>Journal of Clinical Oncology</i> , 2010, 28, 2512-2519.	1.6	877
151	Abrogation of the G2 Checkpoint by Inhibition of Wee-1 Kinase Results in Sensitization of p53-Deficient Tumor Cells to DNA-Damaging Agents. <i>Current Clinical Pharmacology</i> , 2010, 5, 186-191.	0.6	95
152	Coadministration of Ritonavir Strongly Enhances the Apparent Oral Bioavailability of Docetaxel in Patients with Solid Tumors. <i>Clinical Cancer Research</i> , 2009, 15, 4228-4233.	7.0	66
153	Protein versus DNA as a marker for peripheral blood mononuclear cell counting. <i>Analytical and Bioanalytical Chemistry</i> , 2009, 395, 863-867.	3.7	13
154	Liquid chromatography-tandem mass spectrometric assay for the light sensitive tyrosine kinase inhibitor axitinib in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009, 877, 4090-4096.	2.3	43
155	The bioanalysis of trastuzumab in human serum using precipitate-enhanced ellipsometry. <i>Analytical Biochemistry</i> , 2009, 393, 73-79.	2.4	7
156	Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from <i>BRCA</i> Mutation Carriers. <i>New England Journal of Medicine</i> , 2009, 361, 123-134.	27.0	3,312
157	CYP2C9 and CYP2C19 Polymorphic Forms Are Related to Increased Indisulam Exposure and Higher Risk of Severe Hematologic Toxicity. <i>Clinical Cancer Research</i> , 2007, 13, 2970-2976.	7.0	30
158	Population Pharmacokinetics and Pharmacodynamics of Doxorubicin and Cyclophosphamide in Breast Cancer Patients. <i>Clinical Pharmacokinetics</i> , 2007, 46, 1051-1068.	3.5	42
159	Validated assay for the simultaneous determination of the anti-cancer agent gemcitabine and its metabolite 2- $\beta$ -difluorodeoxyuridine in human plasma by high-performance liquid chromatography with tandem mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2007, 21, 2312-2322.	1.5	32
160	Metabolism of trabectedin (ET-743, Yondelis $\text{\textcircled{C}}$ ) in patients with advanced cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 59, 825-837.	2.3	29
161	Herb-Drug Interactions in Oncology: Focus on Mechanisms of Induction. <i>Oncologist</i> , 2006, 11, 742-752.	3.7	198
162	Quantification of Farnesylmethylcysteine in Lysates of Peripheral Blood Mononuclear Cells Using Liquid Chromatography Coupled with Electrospray Tandem Mass Spectrometry: A Pharmacodynamic Assay for Farnesyl Transferase Inhibitors. <i>Analytical Chemistry</i> , 2006, 78, 2617-2622.	6.5	4

#	ARTICLE	IF	CITATIONS
163	Quantitative Effect of Gender, Age, Liver Function, and Body Size on the Population Pharmacokinetics of Paclitaxel in Patients with Solid Tumors. <i>Clinical Cancer Research</i> , 2006, 12, 2150-2157.	7.0	97
164	Absence of N-linked glycosylation does not affect plasma membrane localization of breast cancer resistance protein (BCRP/ABCG2). <i>Cancer Chemotherapy and Pharmacology</i> , 2005, 56, 344-350.	2.3	67
165	Development of Farnesyl Transferase Inhibitors: A Review. <i>Oncologist</i> , 2005, 10, 565-578.	3.7	256
166	Detection of Single Nucleotide Polymorphisms in the ABCG2 Gene in a Dutch Population. <i>Molecular Diagnosis and Therapy</i> , 2005, 5, 123-131.	3.3	46
167	PRESCRIPTION ERROR RESULTING IN VALPROIC ACID INTOXICATION. <i>Journal of the American Geriatrics Society</i> , 2004, 52, 2142-2143.	2.6	2
168	Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice. <i>Investigational New Drugs</i> , 2004, 22, 219-229.	2.6	71
169	Cytotoxicity of the organic ruthenium anticancer drug Nami-A is correlated with DNA binding in four different human tumor cell lines. <i>Cancer Chemotherapy and Pharmacology</i> , 2004, 54, 71-78.	2.3	85
170	Liquid chromatographic assay for the cyclic depsipeptide aplidine, a new marine antitumor drug, in whole blood using derivatization with trans-4-hydrazino-2-stilbazole. <i>Biomedical Chromatography</i> , 2004, 18, 16-20.	1.7	7
171	A Phase I and Pharmacological Study with Imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a Novel Ruthenium Anticancer Agent. <i>Clinical Cancer Research</i> , 2004, 10, 3717-3727.	7.0	781
172	Drug interactions in oncology. <i>Lancet Oncology</i> , The, 2004, 5, 489-496.	10.7	243
173	Urinary and fecal excretion of topotecan in patients with malignant solid tumours. <i>Cancer Chemotherapy and Pharmacology</i> , 2002, 50, 59-64.	2.3	30
174	Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors. <i>Clinical Pharmacology and Therapeutics</i> , 2002, 71, 334-348.	4.7	69
175	Expression of the breast cancer resistance protein in breast cancer. <i>Clinical Cancer Research</i> , 2002, 8, 1068-74.	7.0	93
176	Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. <i>Cancer Research</i> , 2002, 62, 6158-64.	0.9	116
177	Population pharmacokinetics of thioTEPA and its active metabolite TEPA in patients undergoing high-dose chemotherapy. <i>British Journal of Clinical Pharmacology</i> , 2001, 51, 61-70.	2.4	21
178	Phase I and Pharmacokinetic Study of Oral Paclitaxel. <i>Journal of Clinical Oncology</i> , 2000, 18, 2468-2475.	1.6	83
179	Validation of techniques for the prediction of carboplatin exposure: Application of Bayesian methods. <i>Clinical Pharmacology and Therapeutics</i> , 2000, 67, 621-630.	4.7	44
180	Clinical Relevance: Drug-Drug Interactions, Pharmacokinetics, Pharmacodynamics, and Toxicity. , 0, , 747-880.		5

#	ARTICLE	IF	CITATIONS
181	The Role of ABC Transporters at the Intestinal Barrier. , 0, , 385-409.		0